The Centre of Liver Research and NIHR Biomedical Research Unit in Liver Diseases, University of Birmingham and University Hospital Birmingham NHS Trust, UK.
The Centre of Liver Research and NIHR Biomedical Research Unit in Liver Diseases, University of Birmingham and University Hospital Birmingham NHS Trust, UK.
Atherosclerosis. 2015 Mar;239(1):192-202. doi: 10.1016/j.atherosclerosis.2015.01.001. Epub 2015 Jan 13.
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and the incidence of which is rising rapidly due to the increasing epidemic of obesity in both adults and children. The initial accumulation of fat followed by subsequent inflammation is central to the development of liver damage, and is critically influenced by host factors including age, gender, presence of diabetes, genetic polymorphisms and more recently by the gut microbiome. An increasing body of data suggest that NAFLD is also an independent risk factor of cardiovascular disease, which remains the commonest cause of mortality in such patients. This review focusses on the pathogenesis of NAFLD, and the evolution of new approaches to the management and treatment of NAFLD.
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏表现，由于肥胖在成人和儿童中的流行率不断上升，其发病率也在迅速上升。脂肪的最初积累，随后的炎症是肝损伤发展的核心，宿主因素包括年龄、性别、糖尿病的存在、遗传多态性以及最近的肠道微生物组都对其有重要影响。越来越多的证据表明，NAFLD 也是心血管疾病的独立危险因素，这仍然是此类患者最常见的死亡原因。这篇综述重点介绍了 NAFLD 的发病机制，以及 NAFLD 管理和治疗新方法的演变。
